Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 4
2004 6
2005 3
2006 9
2007 1
2008 4
2009 9
2010 8
2011 8
2012 3
2013 7
2014 13
2015 10
2016 19
2017 12
2018 13
2019 24
2020 28
2021 39
2022 37
2023 49
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. Among authors: pignata s. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, Harter P, Murphy CG, Wang J, Noble E, Esteves B, Method M, Coleman RL. Matulonis UA, et al. Among authors: pignata s. J Clin Oncol. 2023 May 1;41(13):2436-2445. doi: 10.1200/JCO.22.01900. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716407 Free PMC article. Clinical Trial.
Endometrial carcinosarcoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Caruso G, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher DM, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Ramirez PT, Mariani A, Leitao M, Makker V, Abu-Rustum NR, Vergote I, Zannoni G, Tan D, McCormack M, Paolini B, Bini M, Raspagliesi F, Benedetti Panici P, Di Donato V, Muzii L, Colombo N, Pignata S, Scambia G, Monk BJ. Bogani G, et al. Among authors: pignata s. Int J Gynecol Cancer. 2023 Feb 6;33(2):147-174. doi: 10.1136/ijgc-2022-004073. Int J Gynecol Cancer. 2023. PMID: 36585027 Review.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: pignata s. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: pignata s. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Among authors: pignata s. Gynecol Oncol. 2021 Jul;162(1):226-234. doi: 10.1016/j.ygyno.2021.04.029. Epub 2021 Apr 30. Gynecol Oncol. 2021. PMID: 33934848 Free PMC article. Review.
Clear cell carcinoma of the endometrium.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Vaughan MM, Takano M, Provencher D, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Kim JW, Candido Dos Reis FJ, Mariani A, Leitao MM Jr, Makker V, Rustum NA, Vergote I, Zannoni GF, Tan DSP, McCormack M, Bini M, Lopez S, Raspagliesi F, Panici PB, di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Among authors: pignata s. Gynecol Oncol. 2022 Mar;164(3):658-666. doi: 10.1016/j.ygyno.2022.01.012. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063279 Review.
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I; innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Coleman RL, et al. Among authors: pignata s. Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9. Lancet Oncol. 2021. PMID: 33845034 Clinical Trial.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Pujade-Lauraine E, et al. Among authors: pignata s. Lancet Oncol. 2017 Sep;18(9):1274-1284. doi: 10.1016/S1470-2045(17)30469-2. Epub 2017 Jul 25. Lancet Oncol. 2017. PMID: 28754483 Free article. Clinical Trial.
Gestational choriocarcinoma.
Bogani G, Ray-Coquard I, Mutch D, Vergote I, Ramirez PT, Prat J, Concin N, Ngoi NYL, Coleman RL, Enomoto T, Takehara K, Denys H, Lorusso D, Takano M, Sagae S, Wimberger P, Segev Y, Kim SI, Kim JW, Herrera F, Mariani A, Brooks RA, Tan D, Paolini B, Chiappa V, Longo M, Raspagliesi F, Benedetti Panici P, Di Donato V, Caruso G, Colombo N, Pignata S, Zannoni G, Scambia G, Monk BJ. Bogani G, et al. Among authors: pignata s. Int J Gynecol Cancer. 2023 Oct 2;33(10):1504-1514. doi: 10.1136/ijgc-2023-004704. Int J Gynecol Cancer. 2023. PMID: 37758451 Review.
290 results